Boston Scientific’s pulsed field ablation device matches standard of care in AFib trial
www.medtechdive.com/news/BSX-boston-scientific-pulsed-field-ablation-study/691961/
1 Users
0 Comments
2 Highlights
0 Notes
Tags
Top Highlights
Despite that concern, analysts at BTIG and other companies were enthusiastic about the results, with the team at RBC Capital Markets forecasting “conversion of 80% to 90% of the market over a 2-3 year period.”
The approach has delivered data that show PFA is at least a match for existing AFib treatments and could drive the transformation of electrophysiology.
Ready to highlight and find good content?
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.